The main objective of the Boston University Pilot and Feasibility (P&F) Program is to catalyze transformative advances in both translational and basic diabetes research, expanding and broadening the innovative parent Joslin P&F program. The new program would be integrated into the parent Joslin P&F program and will adopt its administrative and scientific policies and infrastructure. The program will have two main components: a regional Computational Systems Biology program and a Boston University Medical Center based new investigator program. The majority of the researchers enrolled in the new Computational Systems Biology program are either new or well-established systems biology researchers at BU, MIT or Harvard with limited prior research in diabetes or metabolic diseases. Thus, the scientific benefits from this program are expected to be high since these researchers bring a substantial prior track record in systems biology or network research successfully applied in other biomedical areas, but they have not previously worked in the biology, genetics or translational aspects of diabetes. The BU Medical Center program will emphasize funding new investigators who work in areas complementary to the focus areas of the Joslin primary P&F program and will include cardiovascular complications related to diabetes and obesity.
The new Pilot and Feasibility Grant Program at Boston University provides seed grants to attract new researchers to the diabetes field. It specifically funds 1. New investigators in the diabetes field who have not previously received substantial NIH funding;2. Experienced investigators in the diabetes field who wish to strike out in a novel direction;and 3. Investigators from other fields embarking on a diabetes-related project for the first time.
|Rao, Tata Nageswara; Gupta, Manoj K; Softic, Samir et al. (2018) Attenuation of PKC? enhances metabolic activity and promotes expansion of blood progenitors. EMBO J 37:|
|Bauman, Viviana; Sturkey, Adaya C; Sherafat-Kazemzadeh, Rosa et al. (2018) Factitious hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 19:823-831|
|Stanford, Kristin I; Rasmussen, Morten; Baer, Lisa A et al. (2018) Paternal Exercise Improves Glucose Metabolism in Adult Offspring. Diabetes 67:2530-2540|
|Park, Kyoungmin; Li, Qian; Evcimen, Net Da? et al. (2018) Exogenous Insulin Infusion Can Decrease Atherosclerosis in Diabetic Rodents by Improving Lipids, Inflammation, and Endothelial Function. Arterioscler Thromb Vasc Biol 38:92-101|
|Lynes, Matthew D; Shamsi, Farnaz; Sustarsic, Elahu Gosney et al. (2018) Cold-Activated Lipid Dynamics in Adipose Tissue Highlights a Role for Cardiolipin in Thermogenic Metabolism. Cell Rep 24:781-790|
|Schuster, Cornelia; Jonas, Franziska; Zhao, Fangzhu et al. (2018) Peripherally induced regulatory T cells contribute to the control of autoimmune diabetes in the NOD mouse model. Eur J Immunol 48:1211-1216|
|Laguna Sanz, Alejandro J; Mulla, Christopher M; Fowler, Kristen M et al. (2018) Design and Clinical Evaluation of a Novel Low-Glucose Prediction Algorithm with Mini-Dose Stable Glucagon Delivery in Post-Bariatric Hypoglycemia. Diabetes Technol Ther 20:127-139|
|Bhattacharya, Asmita; Sun, Shengyi; Wang, Heting et al. (2018) Hepatic Sel1L-Hrd1 ER-associated degradation (ERAD) manages FGF21 levels and systemic metabolism via CREBH. EMBO J 37:|
|Rabiee, Atefeh; Krüger, Marcus; Ardenkjær-Larsen, Jacob et al. (2018) Distinct signalling properties of insulin receptor substrate (IRS)-1 and IRS-2 in mediating insulin/IGF-1 action. Cell Signal 47:1-15|
|Cai, Weikang; Xue, Chang; Sakaguchi, Masaji et al. (2018) Insulin regulates astrocyte gliotransmission and modulates behavior. J Clin Invest 128:2914-2926|
Showing the most recent 10 out of 1120 publications